bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 4 from Zoledronic Acid Has Differential Antitumor Activity in the Pre- and Postmenopausal Bone Microenvironment In Vivo
Authors: Ottewell Penelope D. , Wang Ning , Brown Hannah K. , Reeves Kimberly J. , Fowles C. Anne , Croucher Peter I. , Eaton Colby L. , Holen Ingunn
Published: April 2023

PDF file - 166KB, Effects of 4 week estradiol supplementation on bone turnover in mouse tibiae. Histograms showing a) numbers of osteoclasts and b) numbers of osteoblasts per mm of bone. Representative images of control and estradiol tibiae, a) by microCT and b) on H&E satined histological sections.
Table S3 from miR-200b and miR-200c as Prognostic Factors and Mediators of Gastric Cancer Cell Progression
Authors: Tang Hailin , Deng Min , Tang Yunyun , Xie Xinhua , Guo Jiaoli , Kong Yanan , Ye Feng , Su Qi , Xie Xiaoming
Published: April 2023

Table S3 - PDF file 67K, Univariate and multivariable Cox regression analysis of relapse-free survival (Cox proportional hazards regression model)
Related Article from It Takes Two to Tango: Dual Inhibition of PI3K and MAPK in Rhabdomyosarcoma
Authors: Jahangiri Arman , Weiss William A.
Published: April 2023

Related Article from It Takes Two to Tango: Dual Inhibition of PI3K and MAPK in Rhabdomyosarcoma
Supplementary Figure 1 from Reducing TNF Receptor 2+ Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients
Authors: Govindaraj Chindu , Tan Peter , Walker Patricia , Wei Andrew , Spencer Andrew , Plebanski Magdalena
Published: April 2023

PDF file - 1479K, Comparison of the absolute cell counts of T cells and Tregs.
Supplementary Figure 2 from High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition
Authors: Wik Elisabeth , Birkeland Even , Trovik Jone , Werner Henrica M.J. , Hoivik Erling A. , Mjos Siv , Krakstad Camilla , Kusonmano Kanthida , Mauland Karen , Stefansson Ingunn M. , Holst Frederik , Petersen Kjell , Oyan Anne M. , Simon Ronald , Kalland Karl H. , Ricketts William , Akslen Lars A. , Salvesen Helga B.
Published: April 2023

PDF file - 40K, Unsupervised hierarchical clustering of gene expression data from endometrial carcinoma. The pStathmin(S38) high cases are significantly overrepresented in two of the clusters with aggressive tumors.
Supplementary Figures 1 - 5 from ZEB1 Promotes Invasiveness of Colorectal Carcinoma Cells through the Opposing Regulation of uPA and PAI-1
Authors: Sánchez-Tilló Ester , de Barrios Oriol , Siles Laura , Amendola Pier G. , Darling Douglas S. , Cuatrecasas Miriam , Castells Antoni , Postigo Antonio
Published: April 2023

PDF file - 4604K
Supplementary Table 2 from Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization
Authors: McCune Jeannine S. , Bemer Meagan J. , Barrett Jeffrey S. , Scott Baker K. , Gamis Alan S. , Holford Nicholas H.G.
Published: April 2023

PDF file 45K, Detailed description of patient population characteristics
Supplementary Figures from Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization
Authors: McCune Jeannine S. , Bemer Meagan J. , Barrett Jeffrey S. , Scott Baker K. , Gamis Alan S. , Holford Nicholas H.G.
Published: April 2023

PDF file 181K, Figures of 1) the association of dosing weight to actual and predicted total body weights; and 2) prediction corrected visual predictive checks
Supplementary Figure 4 from Reciprocal Interactions between Tumor-Associated Macrophages and CD44-Positive Cancer Cells via Osteopontin/CD44 Promote Tumorigenicity in Colorectal Cancer
Authors: Rao Guanhua , Wang Hongyi , Li Baowei , Huang Li , Xue Danfeng , Wang Xiaohui , Jin Haijing , Wang Jun , Zhu Yushan , Lu Youyong , Du Lei , Chen Quan
Published: April 2023

PDF file - 1070K, SDS-PAGE analysis of purified OPN.
Supplementary Figures 1 - 6 from Cidofovir: A Novel Antitumor Agent for Glioblastoma
Authors: Hadaczek Piotr , Ozawa Tomoko , Soroceanu Liliana , Yoshida Yasuyuki , Matlaf Lisa , Singer Eric , Fiallos Estefania , James C. David , Cobbs Charles S.
Published: April 2023

PDF file - 508K, Figure S1. CDV treatment inhibits viral gene expression in a primary GBM, endogenously infected with HMCV. Figure S2. Control to viability of U87MG after infection with HCMV. Figure S3. Treatment with Cidofovir inhibits global HCMV gene expression. Figure S4. SF7796 primary derived GBM (used for in vivo experiments) is endogenously infected with HCMV. Figure S5. Treatment of normal and tumor cells with CDV in vitro. Figure S6. CDV treatment significantly suppresses the expression of HCMV in established human SF7796 xenografts in vivo.
Supplementary Figure Legend, Tables 1 - 2 from Margin-Infiltrating CD20+ B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma
Authors: Shi Jie-Yi , Gao Qiang , Wang Zhi-Chao , Zhou Jian , Wang Xiao-Ying , Min Zhi-Hui , Shi Ying-Hong , Shi Guo-Ming , Ding Zhen-Bin , Ke Ai-Wu , Dai Zhi , Qiu Shuang-Jian , Song Kang , Fan Jia
Published: April 2023

PDF file - 93K, Supplementary Figure Legend; Supplemental Table S1. Correlation between CD20+ Supplemental Table S1. Correlation between CD20+ B lymphocytes and clinicopathologic characteristics in the validation cohort (n=200); Supplemental Table S2. Univariate analyses of factors associated with survival and recurrence (n=120)
Supplementary Table 3 from The ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic Carcinoma Cells
Authors: Hayman Thomas J. , Wahba Amy , Rath Barbara H. , Bae Heekyong , Kramp Tamalee , Shankavaram Uma T. , Camphausen Kevin , Tofilon Philip J.
Published: April 2023

PDF - 89K, Functions associated with the top networks for the genes no longer decreased by radiation after INK128 treatment.
Supplementary Table 2 from The ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic Carcinoma Cells
Authors: Hayman Thomas J. , Wahba Amy , Rath Barbara H. , Bae Heekyong , Kramp Tamalee , Shankavaram Uma T. , Camphausen Kevin , Tofilon Philip J.
Published: April 2023

PDF - 99K, Functions associated with the top networks corresponding to the genes whose radiation-induced upregulation was inhibited by INK128
Supplementary Figures from Identification of Lethal microRNAs Specific for Head and Neck Cancer
Authors: Lindenbergh-van der Plas Marlon , Martens-de Kemp Sanne R. , de Maaker Michiel , van Wieringen Wessel N. , Ylstra Bauke , Agami Reuven , Cerisoli Francesco , Leemans C. René , Braakhuis Boudewijn J.M. , Brakenhoff Ruud H.
Published: April 2023

PDF file, 96K, Supplementary Figure S1 First validation of the identified 19 microRNAs that seemed to elicit a tumor-selective lethal effect. Supplementary Figure S2 Effect of the six tumor-selective microRNAs on non-HNSCC cell lines. Supplementary Figure S3 Phenotypic effect of miR-181a overexpression in time, either when introduced by retroviral transduction or transient transfection in HNSCC cell line VU-SCC-120. Supplementary Figure S4 ATM expression after transient transfection of expression constructs with ATM and a kinase-dead ATM mutant lacking the 3'UTR of ATM.
Supplementary Figure 5 from Inactivation or Loss of TTP Promotes Invasion in Head and Neck Cancer via Transcript Stabilization and Secretion of MMP9, MMP2, and IL-6
Authors: Van Tubergen Elizabeth A. , Banerjee Rajat , Liu Min , Broek Robert Vander , Light Emily , Kuo Shiuhyang , Feinberg Stephen E. , Willis Amanda L. , Wolf Gregory , Carey Thomas , Bradford Carol , Prince Mark , Worden Francis P. , Kirkwood Keith L. , D'Silva Nisha J.
Published: April 2023

PDF file - 4600K, Supplementary Figure S5. TTP regulates the stability of transcripts IL-6, MMP9 and MMP2 via the 3'-UTR. (A) Left three panels: IL-6, MMP9 and MMP2 mRNA levels were quantified via Q-RT-PCR from UM-SCC-81B cells transfected with NT and siTTP. Data are representative of two independent experiments with three replicates in each experiment. Right Panel: Whole-cell lysates were immunoblotted with TTP and actin antibodies. Signal intensity was quantified, normalized to actin, and expressed as percent of NT. (B) Left three panels: UM-SCC-81B cells transfected with NT or siTTP were then co-transfected with a luciferase reporter construct containing the 3'-UTR of IL-6, MMP9 or MMP2 and a Renilla construct for normalization. Experiments were performed in triplicate with three replicates in each experiment. Right panel: Whole cell lysates were immunoblotted with TTP and actin antibodies. Signal intensity was quantified, normalized to actin, and expressed as percent of NT. (*p<0.01)
Supplementary Figure Legend from Oncogenic Function of SCCRO5/DCUN1D5 Requires Its Neddylation E3 Activity and Nuclear Localization
Authors: Bommeljé Claire C. , Weeda Víola B. , Huang Guochang , Shah Kushyup , Bains Sarina , Buss Elizabeth , Shaha Manish , Gönen Mithat , Ghossein Ronald , Ramanathan Suresh Y. , Singh Bhuvanesh
Published: April 2023

PDF file - 77K
Supplementary Figure 1 from Oncogenic Function of SCCRO5/DCUN1D5 Requires Its Neddylation E3 Activity and Nuclear Localization
Authors: Bommeljé Claire C. , Weeda Víola B. , Huang Guochang , Shah Kushyup , Bains Sarina , Buss Elizabeth , Shaha Manish , Gönen Mithat , Ghossein Ronald , Ramanathan Suresh Y. , Singh Bhuvanesh
Published: April 2023

PDF file - 918K, A, Schematic representation of domain structures of SCCRO and its paralogues. B, Alignment of PONY domain of SCCRO and its paralogues. SCCRO5 residues critical for binding to neddylation components are shown.
Supplementary Table 1 from Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
Authors: Angevin Eric , Lopez-Martin Jose A. , Lin Chia-Chi , Gschwend Jürgen E. , Harzstark Andrea , Castellano Daniel , Soria Jean-Charles , Sen Paramita , Chang Julie , Shi Michael , Kay Andrea , Escudier Bernard
Published: April 2023

PDF file - 49K, Supplemental Table 1. Criteria for defining dose-limiting criteria
Supplementary Figure 3 from BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Authors: Frederick Dennie T. , Piris Adriano , Cogdill Alexandria P. , Cooper Zachary A. , Lezcano Cecilia , Ferrone Cristina R. , Mitra Devarati , Boni Andrea , Newton Lindsay P. , Liu Chengwen , Peng Weiyi , Sullivan Ryan J. , Lawrence Donald P. , Hodi F. Stephen , Overwijk Willem W. , Lizée Gregory , Murphy George F. , Hwu Patrick , Flaherty Keith T. , Fisher David E. , Wargo Jennifer A.
Published: April 2023

PDF file - 19K, Melanoma antigen expression is decreased at time of progression.
Supplementary Figure Legend from Epstein-Barr Virus DNA Load in Nasopharyngeal Brushings and Whole Blood in Nasopharyngeal Carcinoma Patients before and after Treatment
Authors: Adham Marlinda , Greijer Astrid E. , Verkuijlen Sandra A.W.M. , Juwana Hedy , Fleig Sabine , Rachmadi Lisnawati , Malik Octavia , Kurniawan A.N. , Roezin Averdi , Gondhowiardjo Soehartati , Atmakusumah Djumhana , Stevens Servi J.C. , Hermani Bambang , Tan I. Bing , Middeldorp Jaap M.
Published: April 2023

PDF file - 53K
Supplementary Tables and Figures from Hypoxic Activation of the PERK/eIF2α Arm of the Unfolded Protein Response Promotes Metastasis through Induction of LAMP3
Authors: Mujcic Hilda , Nagelkerke Anika , Rouschop Kasper M.A. , Chung Stephen , Chaudary Naz , Span Paul N. , Clarke Blaise , Milosevic Michael , Sykes Jenna , Hill Richard P. , Koritzinsky Marianne , Wouters Bradly G.
Published: April 2023

Supplementary Tables and Figures - PDF file 274K, 34-C orthotopic xenografts; Supplementary figure 10: Microvessel density and hVEGF expression in shLAMP3 orthotopic xenografts; Supplementary figure 11: Hypoxic fraction shLAMP3 orthotopic xenografts; Supplementary figure 12: LAMP3 promotes colony formation in soft agar; Supplementary figure 13: Transwell migration LAMP3 deficient HeLa cells; Supplementary figure 14: Scratch wound healing assay
Supplementary Figure 3 from Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model
Authors: Morales-Kastresana Aizea , Sanmamed Miguel F. , Rodriguez Inmaculada , Palazon Asis , Martinez-Forero Ivan , Labiano Sara , Hervas-Stubbs Sandra , Sangro Bruno , Ochoa Carmen , Rouzaut Ana , Azpilikueta Arantza , Bolaños Elixabet , Jure-Kunkel Maria , Gütgemann Ines , Melero Ignacio
Published: April 2023

PDF file - 946K, Anti-CTLA-4 mAb treatment fails to extend survival of c-myc OVA tg+
Supplementary Figures 1 - 7 from Expression Signature Defined by FOXM1–CCNB1 Activation Predicts Disease Recurrence in Non–Muscle-Invasive Bladder Cancer
Authors: Kim Seon-Kyu , Roh Yun-Gil , Park Kiejung , Kang Tae-Hong , Kim Wun-Jae , Lee Ju-Seog , Leem Sun-Hee , Chu In-Sun
Published: April 2023

PDF file - 490KB, Supplementary Figure S1. Independent validation of the prognostic value of the signature. Supplementary Figure S2. Prediction of a response to intravesical therapy in the two subgroups with the CCNB1 signature in the European cohort. Supplementary Figure S3. Gene set enrichments analysis of genes in CCNB1 signature. Supplementary Figure S4. FOXM1 networks enriched with genes associated with disease recurrence. Supplementary Figure S5. Comparison of expression levels between high CCNB1 cluster (HC) and low CCNB1 cluster (LC) patients. Supplementary Figure S6. Comparison of expression levels of genes involved in Fanconi anemia family between high CCNB1 cluster (HC) and low CCNB1 cluster (LC) patients. Supplementary Figure S7. Schematic diagram of workflow.
Supporting video 2 from A NOTCH3 Transcriptional Module Induces Cell Motility in Neuroblastoma
Authors: van Nes Johan , Chan Alvin , van Groningen Tim , van Sluis Peter , Koster Jan , Versteeg Rogier
Published: April 2023

Supporting video 2 - MOV file 1047K, IMR32-NOTCH3IC cells cultured with doxycycline. Note the fast-moving presence of different cells.
Supplementary Table 4a from Profiling Three-Dimensional Nuclear Telomeric Architecture of Myelodysplastic Syndromes and Acute Myeloid Leukemia Defines Patient Subgroups
Authors: Gadji Macoura , Adebayo Awe Julius , Rodrigues Prerana , Kumar Rajat , Houston Donald S. , Klewes Ludger , Dièye Tandakha Ndiaye , Rego Eduardo Magalhães , Passetto Roberto Falcão , de Oliveira Fábio Morato , Mai Sabine
Published: April 2023

PDF file, 44KB, Telomere parameters according to IPSS classification of MDS.
Supplementary Table 4 from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer
Authors: Tian Junqiang , Zhao Hongjuan , Nolley Rosalie , Reese Stephen W. , Young Sarah R. , Li Xuejun , Peehl Donna M. , Knox Susan J.
Published: April 2023

PDF file, 223KB, RT-qPCR validation of microarray data.
Supplementary Figure Legends from A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Authors: Beatty Gregory L. , Torigian Drew A. , Chiorean E. Gabriela , Saboury Babak , Brothers Alex , Alavi Abass , Troxel Andrea B. , Sun Weijing , Teitelbaum Ursina R. , Vonderheide Robert H. , O'Dwyer Peter J.
Published: April 2023

Supplementary Figure Legends - PDF file 64K, Supplementary Figure Legends
Supplementary Table 3 from Darinaparsin: Solid Tumor Hypoxic Cytotoxin and Radiosensitizer
Authors: Tian Junqiang , Zhao Hongjuan , Nolley Rosalie , Reese Stephen W. , Young Sarah R. , Li Xuejun , Peehl Donna M. , Knox Susan J.
Published: April 2023

PDF file, 66KB, Serum biochemistry panel.
Supplementary Figure Legend from miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive Potential In Vitro
Authors: Mulrane Laoighse , Madden Stephen F. , Brennan Donal J. , Gremel Gabriela , McGee Sharon F. , McNally Sara , Martin Finian , Crown John P. , Jirström Karin , Higgins Desmond G. , Gallagher William M. , O'Connor Darran P.
Published: April 2023

PDF file - 56K
Supplementary Figure 1 from Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide
Authors: Zimmerman Eric I. , Hu Shuiying , Roberts Justin L. , Gibson Alice A. , Orwick Shelley J. , Li Lie , Sparreboom Alex , Baker Sharyn D.
Published: April 2023

PDF file - 39K, Estradiol-17β-D-glucuronide transport in HEK293 OATP1B1 and OATP1B3 cells.
Supplementary Data from Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer
Authors: Dennison Jennifer B. , Molina Jennifer R. , Mitra Shreya , González-Angulo Ana M. , Balko Justin M. , Kuba María G. , Sanders Melinda E. , Pinto Joseph A. , Gómez Henry L. , Arteaga Carlos L. , Brown Robert E. , Mills Gordon B.
Published: April 2023

Supplementary Data - PDF file 89K, Supplementary Methods Tissue microarray (TMA) of triple-negative breast cancers
Supplementary Tables 1A - 1B from EZH2 Mutations in Follicular Lymphoma from Different Ethnic Groups and Associated Gene Expression Alterations
Authors: Guo Shuangping , Chan John K.C. , Iqbal Javeed , McKeithan Timothy , Fu Kai , Meng Bin , Pan Yi , Cheuk Wah , Luo Donglan , Wang Ruian , Zhang Weiwei , Greiner Timothy C. , Chan Wing C.
Published: April 2023

PDF file - 58KB, Grade of TCL1A expression in FL.
Supplementary Figure Legend from Functional Genetic Screens Identify Genes Essential for Tumor Cell Survival in Head and Neck and Lung Cancer
Authors: Martens-de Kemp Sanne R. , Nagel Remco , Stigter-van Walsum Marijke , van der Meulen Ida H. , van Beusechem Victor W. , Braakhuis Boudewijn J.M. , Brakenhoff Ruud H.
Published: April 2023

PDF file - 100K
Supplementary Figure 6 from Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs
Authors: Patwardhan Parag P. , Surriga Oliver , Beckman Michael J. , de Stanchina Elisa , Dematteo Ronald P. , Tap William D. , Schwartz Gary K.
Published: April 2023

PDF file - 188KB, Effect of PLX5622, a c-Fms specific inhibitor, on MPNST tumor growth.
Supplementary Figure 3 from Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs
Authors: Patwardhan Parag P. , Surriga Oliver , Beckman Michael J. , de Stanchina Elisa , Dematteo Ronald P. , Tap William D. , Schwartz Gary K.
Published: April 2023

PDF file - 76KB, Effect of PLX3397 on phosphorylation of PDGFRbeta.
Supplementary Methods and Tables and Figures from DNA Methylation of the SLC16A3 Promoter Regulates Expression of the Human Lactate Transporter MCT4 in Renal Cancer with Consequences for Clinical Outcome
Authors: Fisel Pascale , Kruck Stephan , Winter Stefan , Bedke Jens , Hennenlotter Jörg , Nies Anne T. , Scharpf Marcus , Fend Falko , Stenzl Arnulf , Schwab Matthias , Schaeffeler Elke
Published: April 2023

PDF file, 405K, Supplementary methods, including detailed description of patient cohort, MCT4 immunohistochemical staining and TMA analysis, MCT4 knockdown experiments, Western Blot analysis, RNA isolation and quantification, DNA isolation and promoter methylation analyses, promoter reporter constructs and in vitro methylation, transient transfection and reporter assays as well as statistical analyses. Supplementary Table S1: Comparison of the three independent patient cohorts. Supplementary Table S2: Correlation of MCT4 protein expression in ccRCC tissue with clinicopathological parameters in the TuCP1-cohort. Supplementary Table S3: CpG sites analyzed by the Infinium HumanMethylation450 BeadChip and by MALDI-TOF MS. Supplementary Table S4: Correlation of MCT4 protein expression in ccRCC tissue with clinicopathological parameters in the TuCP2-cohort. Supplementary Table S5: Univariate Cox regression analysis of prognostic factors for survival in the TuCP1-, TuCP2- and the TCGA-cohort. Supplementary Table S6: Results from ROC analysis for survival in the TuCP2- and TCGA-cohort. Supplementary Figure S1: Validation of MCT4 antibody by MCT4 knockdown and representative pictures of stained non-tumor and ccRCC tissue for the evaluation of MCT4 protein expression by the composite IHC score. Supplementary Figure S2: MCT4 protein and mRNA expression and correlation with specific CpG sites in the TuCP2-cohort. Supplementary Figure S3: Kaplan-Meier curve of cancer-specific survival based on percentage of MCT4 protein expression in ccRCC tissue of the TuCP2-cohort. Supplementary Figure S4: DNA methylation at the SLC16A3 promoter in the TCGA-cohort (Infinium Human Methylation 450 Bead Chip) depending on VHL mutations.
Supplementary Figure 1 from Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma
Authors: Chodon Thinle , Comin-Anduix Begoña , Chmielowski Bartosz , Koya Richard C. , Wu Zhongqi , Auerbach Martin , Ng Charles , Avramis Earl , Seja Elizabeth , Villanueva Arturo , McCannel Tara A. , Ishiyama Akira , Czernin Johannes , Radu Caius G. , Wang Xiaoyan , Gjertson David W. , Cochran Alistair J. , Cornetta Kenneth , Wong Deborah J.L. , Kaplan-Lefko Paula , Hamid Omid , Samlowski Wolfram , Cohen Peter A. , Daniels Gregory A. , Mukherji Bijay , Yang Lili , Zack Jerome A. , Kohn Donald B. , Heath James R. , Glaspy John A. , Witte Owen N. , Baltimore David , Economou James S. , Ribas Antoni
Published: April 2023

PDF file - 82KB, TCR transgenic cell therapy manufacture protocol modifications.
Supplementary Tables S1 and S2 from Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis
Authors: Zhong Qian , Peng Hong-Ling , Zhao Xia , Zhang Lin , Hwang Wei-Ting
Published: April 2023

Supplementary Tables S1 and S2. Table S1. Clinical characteristics of the included studies for ovarian cancer. Table S2. Clinical characteristics of the included studies for breast cancer.
Supplemental Tables and Figure Legends from Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma
Authors: Mao Yumeng , Eissler Nina , Blanc Katarina Le , Johnsen John Inge , Kogner Per , Kiessling Rolf
Published: April 2023

Table S1. Statistical comparisons between neurofibroma (NF) and 3 cohorts of human neuroblastoma (NB) tissues. Table S2. Authentication of human neuroblastoma cell lines Table S3. Antibodies and dyes used for flow cytometry. Supplemental Figure Legends
Supplementary Figure 2B from Blocking and Randomization to Improve Molecular Biomarker Discovery
Authors: Qin Li-Xuan , Zhou Qin , Bogomolniy Faina , Villafania Liliana , Olvera Narciso , Cavatore Magali , Satagopan Jaya M. , Begg Colin B. , Levine Douglas A.
Published: April 2023

PDF file - 20KB, Boxplot of TPR and FPR from the simulation study examining various experimental designs of array-to-sample assignment: (b) after quantile normalization.
Supplementary Figure 1 from miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression
Authors: Chen Xuanyu , Wang Xuegang , Ruan Anming , Han Weiwei , Zhao Yan , Lu Xing , Xiao Pei , Shi Hangchuan , Wang Rong , Chen Li , Chen Shaoyong , Du Quansheng , Yang Hongmei , Zhang Xiaoping
Published: April 2023

PDF file - 69K, Statistical analyses of the clinical significance of miR-141 in kidney tumors.
Data Supplement from Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)
Authors: Falchook Gerald S. , Long Georgina V. , Kurzrock Razelle , Kim Kevin B. , Arkenau H.-Tobias , Brown Michael P. , Hamid Omid , Infante Jeffrey R. , Millward Michael , Pavlick Anna , Chin Melvin T. , O'Day Steven J. , Blackman Samuel C. , Curtis C. Martin , Lebowitz Peter , Ma Bo , Ouellet Daniele , Kefford Richard F.
Published: April 2023

Table S1. Treatment-related adverse events of {greater than or equal to} grade 2 reported in at least 5% of patients by dose (3); Table S2. Summary of plasma dabrafenib pharmacokinetic parameters after single-dose administration of dabrafenib gelatin capsules under fasted conditions (dose escalation: Part 1); Table S3. Summary of plasma dabrafenib pharmacokinetic parameters after repeated dose administration of dabrafenib gelatin capsules under fasting conditions on day 8 or day 15 (dose escalation: Part 1).
Supplementary Material from The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Authors: Sánchez-Martín Francisco J. , Bellosillo Beatriz , Gelabert-Baldrich Mariona , Dalmases Alba , Cañadas Israel , Vidal Joana , Martinez Alejandro , Argilés Guillem , Siravegna Giulia , Arena Sabrina , Koefoed Klaus , Visa Laura , Arpí Oriol , Horak Ivan David , Iglesias Mar , Stroh Christopher , Kragh Michael , Rovira Ana , Albanell Joan , Tabernero Josep , Bardelli Alberto , Montagut Clara
Published: April 2023

Figure S1: EGFR mutants binding to CTX, Sym004, PNM Figure S2: Clonogenic assay in EGFR mutants with CTX, Sym004, PNM
Supplemental data from Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients
Authors: Wu S. Peter , Pfeiffer Ruth M. , Ahn Inhye E. , Mailankody Sham , Sonneveld Pieter , van Duin Mark , Munshi Nikhil C. , Walker Brian A. , Morgan Gareth , Landgren Ola
Published: April 2023

Supplemental Table 1 contains a comparison of hazard ratios of Non-MMSET patients at the highest quartile (Q4 Risk) and MMSET patients. Supplemental Table 2 contains a list of gene signatures from sensitivity analyses. Supplemental Table 3 contains a list of 71 genes differentially expressed in MMSET patients vs. Non-MMSET patients. Appendix 1 contains detailed methods of statistical analysis used to determine gene probes associated with survival in Non-MMSET patients.
Data Supplement from Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas
Authors: Seiwert Tanguy Y. , Zuo Zhixiang , Keck Michaela K. , Khattri Arun , Pedamallu Chandra S. , Stricker Thomas , Brown Christopher , Pugh Trevor J. , Stojanov Petar , Cho Juok , Lawrence Michael S. , Getz Gad , Brägelmann Johannes , DeBoer Rebecca , Weichselbaum Ralph R. , Langerman Alexander , Portugal Louis , Blair Elizabeth , Stenson Kerstin , Lingen Mark W. , Cohen Ezra E.W. , Vokes Everett E. , White Kevin P. , Hammerman Peter S.
Published: April 2023

Supplementary Figure S1. Workflow showing the processing and usage of HNSCC samples. Samples with more that 60% tumor content were included for HPV consensus testing and next generation sequencing and other analyses.
Supplementary Methods and Supplementary Tables S1-S6 from Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy
Authors: Khan Sofia , Fagerholm Rainer , Rafiq Sajjad , Tapper William , Aittomäki Kristiina , Liu Jianjun , Blomqvist Carl , Eccles Diana , Nevanlinna Heli
Published: April 2023

Supplementary Methods and Supplementary Tables S1-S6. Supplementary Table S1. Univariate Cox's regression analysis within estrogen receptor positive patients receiving endocrine treatment with stage-1 meta-analysis fullfilling the P-value thresholds. Supplementary Table S2. Association for SNP rs8113308 with clinical and pathological features of the breast cancer tumors in a pooled set of HEBCS GWS, POSH GWS and POSH validation. Supplementary Table S3. Association for SNP rs4767413 with clinical and pathological features of the breast cancer tumors in a pooled set of HEBCS GWS, POSH GWS and POSH validation. Supplementary Table S4. Cis eQTL analysis. Expression in ER positive breast tumor and in ER negative breast tumor from METABRIC. Supplementary Table S5. Peripheral blood eQTL. Supplementary Table S6. Trans eQTL analysis. Expression in ER positive breast tumor and in ER negative breast tumor from METABRIC.
Supplementary Table 1 from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery
Authors: Li Xinqun , Truty Mark A. , Kang Ya'an , Chopin-Laly Xavier , Zhang Ran , Roife David , Chatterjee Deyali , Lin E. , Thomas Ryan M. , Wang Huamin , Katz Matthew H. , Fleming Jason B.
Published: April 2023

Clinicopathologic and oncologic outcome correlation of lumican expression subgroups.
Supplementary Figure S6. from Development of a Model System to Evaluate Local Recurrence in Osteosarcoma and Assessment of the Effects of Bone Morphogenetic Protein-2
Authors: Geller David S. , Singh Michael Y. , Zhang Wendong , Gill Jonathan , Roth Michael E. , Kim Mimi Y. , Xie Xianhong , Singh Christopher K. , Dorfman Howard D. , Villanueva-Siles Esperanza , Park Amy , Piperdi Sajida , Gorlick Richard
Published: April 2023

Supplementary Figure S6. ROC curves for SaOS-2 recurrence vs. average soft-tissue margin length.
Supplemental Figure 6 from High Levels of Antibody that Neutralize B-cell Infection of Epstein–Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma
Authors: Coghill Anna E. , Bu Wei , Nguyen Hanh , Hsu Wan-Lun , Yu Kelly J. , Lou Pei-Jen , Wang Cheng-Ping , Chen Chien-Jen , Hildesheim Allan , Cohen Jeffrey I.
Published: April 2023

Anti-gH/gL antibodies among Prevalent NPC, Incident NPC, and Control participants.
Figure Legends for Supplementary Figures from Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia
Authors: Yamada Atsushi , Horimatsu Takahiro , Okugawa Yoshinaga , Nishida Naoshi , Honjo Hajime , Ida Hiroshi , Kou Tadayuki , Kusaka Toshihiro , Sasaki Yu , Yagi Makato , Higurashi Takuma , Yukawa Norio , Amanuma Yusuke , Kikuchi Osamu , Muto Manabu , Ueno Yoshiyuki , Nakajima Atsushi , Chiba Tsutomu , Boland C. Richard , Goel Ajay
Published: April 2023

Figure Legends for Supplementary Figures
Supplementary Figure 2 from Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer
Authors: Ock Chan-Young , Lee Keun-Wook , Kim Jin Won , Kim Jin-Soo , Kim Tae-Yong , Lee Kyung-Hun , Han Sae-Won , Im Seock-Ah , Kim Tae-You , Kim Woo Ho , Bang Yung-Jue , Oh Do-Youn
Published: April 2023

Supplementary Figure 2. Representative images of HER2 IHC and HER2 FISH
Supplementary Figure S6 from Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells
Authors: Wu Lixian , Yu Jing , Chen Ruijia , Liu Yang , Lou Liguang , Wu Ying , Huang Lisen , Fan Yingjuan , Gao Pinzhang , Huang Meijuan , Wu Yong , Chen Yuanzhong , Xu Jianhua
Published: April 2023

Supplementary Figure S6. The scheme of origins of LSCs and the effects of C086 on LSCs via eradicate leukemia cells at different mature state.
Supplemental Methods and Legends from Chaperonin Containing TCP-1 Protein Level in Breast Cancer Cells Predicts Therapeutic Application of a Cytotoxic Peptide
Authors: Bassiouni Rania , Nemec Kathleen N. , Iketani Ashley , Flores Orielyz , Showalter Anne , Khaled Amr S. , Vishnubhotla Priya , Sprung Robert W. , Kaittanis Charalambos , Perez Jesus M. , Khaled Annette R.
Published: April 2023

Description of supplemental methods and figure legends
Supplementary Table 1 from Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC
Authors: Okada Hideho , Butterfield Lisa H. , Hamilton Ronald L. , Hoji Aki , Sakaki Masashi , Ahn Brian J. , Kohanbash Gary , Drappatz Jan , Engh Johnathan , Amankulor Nduka , Lively Mark O. , Chan Michael D. , Salazar Andres M. , Shaw Edward G. , Potter Douglas M. , Lieberman Frank S.
Published: April 2023

Supplementary Table 1. Associations between baseline IFN-γ ELISPOT values vs. PFS or subsequent IFN-γ ESLIPOT responses
Figure S3 from Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study
Authors: Hekman Marlène C.H. , Boerman Otto C. , de Weijert Mirjam , Bos Desirée L. , Oosterwijk Egbert , Langenhuijsen Hans F. , Mulders Peter F.A. , Rijpkema Mark
Published: April 2023

Images from a kidney lamella after perfusion made with the clinical laparoscopic fluorescence camera showing normal kidney parenchyma (A): visible light image (B): corresponding fluorescence image.
Supplemental Figure Legend from Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma
Authors: Poruk Katherine E. , Blackford Amanda L. , Weiss Matthew J. , Cameron John L. , He Jin , Goggins Michael , Rasheed Zeshaan A. , Wolfgang Christopher L. , Wood Laura D.
Published: April 2023

Legend for the supplemental figures
Supplementary Figure Legends from In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior
Authors: Osada Takuya , Kaneko Kensuke , Gwin William R. , Morse Michael A. , Hobeika Amy , Pogue Brian W. , Hartman Zachary C. , Hughes Philip F. , Haystead Timothy , Lyerly H. Kim
Published: April 2023

Figure Legends for Supplementary Figures 1-4
Supplementary Figure 2 from In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior
Authors: Osada Takuya , Kaneko Kensuke , Gwin William R. , Morse Michael A. , Hobeika Amy , Pogue Brian W. , Hartman Zachary C. , Hughes Philip F. , Haystead Timothy , Lyerly H. Kim
Published: April 2023

Comparison of HS131 HS198 HS152 Imaging
Supplementary figures 1-3 from CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer
Authors: Srivastava Raghvendra M. , Trivedi Sumita , Concha-Benavente Fernando , Gibson Sandra P. , Reeder Carly , Ferrone Soldano , Ferris Robert L.
Published: April 2023

Supplementary Figure S1: Gating strategy to dendritic cells (upper panel), CD56+ NK cells ( lower panel) in the coculture experiment; Supplementary Figure S2A: NK cell viability after Urelumab treatment; Supplementary Figure S2B: Evaluation of CD137 expression in CD56 low, CD56 bright NK cells; Supplementary Figure S2C: Evaluation of CD137 expression in CD56 low, CD56 bright NK cells; Supplementary Figure S3: Immunophenotypic analysis after cetuximab, urelumab combination therapy
Supplemental Figure 2. Kaplan Meier analysis of survival among MCPyV+ and MCPyV- patients according to the density, composition and distribution of the inflammatory infiltrate. from Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma
Authors: Feldmeyer Laurence , Hudgens Courtney W. , Ray-Lyons Genevieve , Nagarajan Priyadharsini , Aung Phyu P. , Curry Jonathan L. , Torres-Cabala Carlos A. , Mino Barbara , Rodriguez-Canales Jaime , Reuben Alexandre , Chen Pei-Ling , Ko Jennifer S. , Billings Steven D. , Bassett Roland L. , Wistuba Ignacio I. , Cooper Zachary A. , Prieto Victor G. , Wargo Jennifer A. , Tetzlaff Michael T.
Published: April 2023

Survival according to CD3 density/mm2 at the periphery (left), center (middle), and hotspot (right) in MCPyV+ MCCs (Top row) versus MCPyV- MCCs (Second row). Survival according to CD8 density/mm2 at the periphery (left), center (middle), and hotspot (right) in MCPyV+ MCCs. (Third Row) versus MCPyV- MCCs (Bottom row). Legend: Patients with cell densities above the median indicated with a dashed line and patients with cell density below the median indicated with a solid line.
Legends to supplementary figures and tables from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition
Authors: Pereira Carolina , Gimenez-Xavier Pol , Pros Eva , Pajares Maria J. , Moro Massimo , Gomez Antonio , Navarro Alejandro , Condom Enric , Moran Sebastian , Gomez-Lopez Gonzalo , Graña Osvaldo , Rubio-Camarillo Miriam , Martinez-Martí Alex , Yokota Jun , Carretero Julian , Galbis Jose M. , Nadal Ernest , Pisano David , Sozzi Gabriella , Felip Enriqueta , Montuenga Luis M. , Roz Luca , Villanueva Alberto , Sanchez-Cespedes Montse
Published: April 2023

Contains the legends for all the supplementary figures and legends
Supplemental Figure 3 from Disruption of Autophagic Degradation with ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis
Authors: Carew Jennifer S. , Espitia Claudia M. , Zhao William , Han Yingchun , Visconte Valeria , Phillips James , Nawrocki Steffan T.
Published: April 2023

Gene expression data
SUPPLEMENTAL MATERIALS from Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Authors: Erbe Amy K. , Wang Wei , Carmichael Lakeesha , Kim KyungMann , Mendonça Eneida A. , Song Yiqiang , Hess Dustin , Reville Patrick K. , London Wendy B. , Naranjo Arlene , Hank Jacquelyn A. , Diccianni Mitchell B. , Reisfeld Ralph A. , Gillies Stephen D. , Matthay Katherine K. , Cohn Susan L. , Hogarty Michael D. , Maris John M. , Park Julie R. , Ozkaynak M. Fevzi , Gilman Andrew L. , Yu Alice L. , Sondel Paul M.
Published: April 2023

Supplementary Methods and Supplementary Table Legends
Supplementary Figure legend from Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
Authors: Sabbaghi MohammadA , Gil-Gómez Gabriel , Guardia Cristina , Servitja Sonia , Arpí Oriol , García-Alonso Sara , Menendez Silvia , Arumi-Uria Montserrat , Serrano Laia , Salido Marta , Muntasell Aura , Martínez-García Maria , Zazo Sandra , Chamizo Cristina , González-Alonso Paula , Madoz-Gúrpide Juan , Eroles Pilar , Arribas Joaquin , Tusquets Ignasi , Lluch Ana , Pandiella Atanasio , Rojo Federico , Rovira Ana , Albanell Joan
Published: April 2023

Supplementary Figure legend
Supplementary Figure 1a from Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib
Authors: Kraft Ira L. , Akshintala Srivandana , Zhu Yuelin , Lei Haiyan , Derse-Anthony Claudia , Dombi Eva , Steinberg Seth M. , Lodish Maya , Waguespack Steven G. , Kapustina Oxana , Fox Elizabeth , Balis Frank M. , Merino Maria J. , Meltzer Paul S. , Glod John W. , Shern Jack F. , Widemann Brigitte C.
Published: April 2023

Patients #1, #3, #4, #6, #7, and #8 experienced progressive disease while on vandetanib therapy. Calcitonin and CEA are shown as percent change from baseline at the start of vandetanib therapy (left y-axis). Tumor size is the sum of longest diameter of lesions per RECISTv1.0 (right y-axis).
Supplementary table 1 from BRCA1-Mutated Estrogen Receptor–Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency
Authors: Lips Esther H. , Debipersad Rashmie D. , Scheerman Caroline E. , Mulder Lennart , Sonke Gabe S. , van der Kolk Lizet E. , Wesseling Jelle , Hogervorst Frans B.L. , Nederlof Petra M.
Published: April 2023

This file shows the significant regions (highlighted in supplementary figure 1) for the comparison B2mutER+ versus SporER+. Subsequently the weighted average frequency in B2mutER+, in SporER+ and the difference between both groups is shown. The last two columns show respectively the p-value and the false discovery rate (q-bound).
figure s2 from Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non–Small Cell Lung Cancer Using Next-Generation Sequencing
Authors: Jin Xiance , Chen Yanfan , Chen Hanbin , Fei Shaoran , Chen Didi , Cai Xiaona , Liu Linger , Lin Baochai , Su Huafang , Zhao Lihao , Su Meng , Pan Huanle , Shen Lanxiao , Xie Deyao , Xie Congying
Published: April 2023

expression pattern of miR-627-5p, miR-128-3p, miR-101-3p, miR-129-5p (A), miR-1246 and miR-155-5p (C) in AC and health controls or miR-150-5p, miR-4459, miR-6873-3p, miR-9-3p (B), miR-149-5p and miR-1246 (D) in SCC and health controls comparison by evaluating threshold cycle number difference (A, B) or calculating 2ÃƒÆ'Ã,Æ'Ãƒâ€šÃ,â¢ÃƒÆ'Ã,â€š-ÃƒÆ'Ã,â€šÃƒâ€šÃ,â³Ct(C, D).
Supplementary figure 1 from BRCA1-Mutated Estrogen Receptor–Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency
Authors: Lips Esther H. , Debipersad Rashmie D. , Scheerman Caroline E. , Mulder Lennart , Sonke Gabe S. , van der Kolk Lizet E. , Wesseling Jelle , Hogervorst Frans B.L. , Nederlof Petra M.
Published: April 2023

This figure shows pairwise comparisons between the BRCA2-mutated ER+ tumors and the sporadic ER+ tumors (upper panel) and the BRCA1-mutated ER+tumors and the sporadic ER+ tumors (lower
figure s1 from Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non–Small Cell Lung Cancer Using Next-Generation Sequencing
Authors: Jin Xiance , Chen Yanfan , Chen Hanbin , Fei Shaoran , Chen Didi , Cai Xiaona , Liu Linger , Lin Baochai , Su Huafang , Zhao Lihao , Su Meng , Pan Huanle , Shen Lanxiao , Xie Deyao , Xie Congying
Published: April 2023

Identification and quantification of total and tumor-derived exosomes from healthy controls, AC and SCC patients
Legends Supplementary Data from BRCA1-Mutated Estrogen Receptor–Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency
Authors: Lips Esther H. , Debipersad Rashmie D. , Scheerman Caroline E. , Mulder Lennart , Sonke Gabe S. , van der Kolk Lizet E. , Wesseling Jelle , Hogervorst Frans B.L. , Nederlof Petra M.
Published: April 2023

This file includes the legends for supplementary figure 1 and supplementary tables 1 and 2
Supplementary material from Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer
Authors: Palapattu Ganesh S. , Salami Simpa S. , Cani Andi K. , Hovelson Daniel H. , Lazo de la Vega Lorena , Vandenberg Kelly R. , Bratley Jarred V. , Liu Chia-Jen , Kunju Lakshmi P. , Montgomery Jeffery S. , Morgan Todd M. , Natarajan Shyam , Huang Jiaoti , Tomlins Scott A. , Marks Leonard S.
Published: April 2023

Supplementary methods
Supplementary Figure 1 from Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer
Authors: Palapattu Ganesh S. , Salami Simpa S. , Cani Andi K. , Hovelson Daniel H. , Lazo de la Vega Lorena , Vandenberg Kelly R. , Bratley Jarred V. , Liu Chia-Jen , Kunju Lakshmi P. , Montgomery Jeffery S. , Morgan Todd M. , Natarajan Shyam , Huang Jiaoti , Tomlins Scott A. , Marks Leonard S.
Published: April 2023

Supplementary Figure 1. Study overview to determine the ability of MRI/ultrasound fusion guided biopsy to resample the same prostate cancer foci using molecular markers of clonality.
Table S3 from Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
Authors: Ma Cynthia X. , Bose Ron , Gao Feng , Freedman Rachel A. , Telli Melinda L. , Kimmick Gretchen , Winer Eric , Naughton Michael , Goetz Matthew P. , Russell Christy , Tripathy Debu , Cobleigh Melody , Forero Andres , Pluard Timothy J. , Anders Carey , Niravath Polly Ann , Thomas Shana , Anderson Jill , Bumb Caroline , Banks Kimberly C. , Lanman Richard B. , Bryce Richard , Lalani Alshad S. , Pfeifer John , Hayes Daniel F. , Pegram Mark , Blackwell Kimberly , Bedard Philippe L. , Al-Kateb Hussam , Ellis Matthew J.C.
Published: April 2023

Table S3
Supplemental figures from Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells
Authors: Patel Viralkumar , Balakrishnan Kumudha , Bibikova Elena , Ayres Mary , Keating Michael J. , Wierda William G. , Gandhi Varsha
Published: April 2023

Figure 1. Structures of acalabrutinib and ibrutinib. A. Chemical structure of acalabrutinib. B. Chemical structure of ibrutinib.
Supplementary Figure S1 from Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
Authors: Mancikova Veronika , Montero-Conde Cristina , Perales-Paton Javier , Fernandez Agustin , Santacana María , Jodkowska Karolina , Inglada-Pérez Lucia , Castelblanco Esmeralda , Borrego Salud , Encinas Mario , Matias-Guiu Xavier , Fraga Mario , Robledo Mercedes
Published: April 2023

Genomic integration in medullary thyroid carcinoma: WORKFLOW
Table S5 from Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
Authors: Audenet François , Isharwal Sumit , Cha Eugene K. , Donoghue Mark T.A. , Drill Esther N. , Ostrovnaya Irina , Pietzak Eugene J. , Sfakianos John P. , Bagrodia Aditya , Murugan Paari , Dalbagni Guido , Donahue Timothy F. , Rosenberg Jonathan E. , Bajorin Dean F. , Arcila Maria E. , Hechtman Jaclyn F. , Berger Michael F. , Taylor Barry S. , Al-Ahmadie Hikmat , Iyer Gopa , Bochner Bernard H. , Coleman Jonathan A. , Solit David B.
Published: April 2023

Univariate and Multivariable Cox regression analysis predicting the risk of bladder recurrence after nephroureterectomy. Each gene mutation was adjusted for sex, prior bladder cancer, location, grade, pT stage.
Supplementary Methods from Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
Authors: Audenet François , Isharwal Sumit , Cha Eugene K. , Donoghue Mark T.A. , Drill Esther N. , Ostrovnaya Irina , Pietzak Eugene J. , Sfakianos John P. , Bagrodia Aditya , Murugan Paari , Dalbagni Guido , Donahue Timothy F. , Rosenberg Jonathan E. , Bajorin Dean F. , Arcila Maria E. , Hechtman Jaclyn F. , Berger Michael F. , Taylor Barry S. , Al-Ahmadie Hikmat , Iyer Gopa , Bochner Bernard H. , Coleman Jonathan A. , Solit David B.
Published: April 2023

Supplementary Methods
Supplementary Materials and Methods from Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer
Authors: Liu Hong , Xu Yiyang , Xiang Jingyi , Long Li , Green Shon , Yang Zhiyuan , Zimdahl Bryan , Lu Jingwei , Cheng Neal , Horan Lucas H. , Liu Bin , Yan Su , Wang Pei , Diaz Juan , Jin Lu , Nakano Yoko , Morales Javier F. , Zhang Pengbo , Liu Lian-xing , Staley Binnaz K. , Priceman Saul J. , Brown Christine E. , Forman Stephen J. , Chan Vivien W. , Liu Cheng
Published: April 2023

Supplementary Materials and Methods
Supplemental Table 2 from Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
Authors: Künkele Annette , Taraseviciute Agne , Finn Laura S. , Johnson Adam J. , Berger Carolina , Finney Olivia , Chang Cindy A. , Rolczynski Lisa S. , Brown Christopher , Mgebroff Stephanie , Berger Michael , Park Julie R. , Jensen Michael C.
Published: April 2023

Supplemental Table 2. Patient and tumor characteristics at time of diagnosis.
Supplemetary file from Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non–Small Cell Lung Cancer
Authors: van der Wekken A.J. , Pelgrim R. , 't Hart N. , Werner N. , Mastik M.F. , Hendriks L. , van der Heijden E.H.F.M. , Looijen-Salamon M. , de Langen A.J. , Staal-van den Brekel J. , Riemersma S. , van den Borne B.E. , Speel E.J.M. , Dingemans A-M.C. , Hiltermann T.J.N. , van den Berg A. , Timens W. , Schuuring E. , Groen H.J.M.
Published: April 2023

In this file a description of all used ALK-FISH and ALK-IHC tests have been put together with table S1
Supplemental Figure 3 from Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
Authors: Künkele Annette , Taraseviciute Agne , Finn Laura S. , Johnson Adam J. , Berger Carolina , Finney Olivia , Chang Cindy A. , Rolczynski Lisa S. , Brown Christopher , Mgebroff Stephanie , Berger Michael , Park Julie R. , Jensen Michael C.
Published: April 2023

Supplemental Figure 3 Monitoring of NHPs after CAR T cell infusion.